Vaxxinity Inc (VAXX)

Vaxxinity Inc. is a biotechnology company focused on developing product candidates for human use in neurology, cardiovascular disease, and coronavirus-related applications. The company’s pipeline includes UB-311, a phase 2 candidate being studied for Alzheimer’s disease; UB-312, a phase 1 candidate targeting Parkinson’s disease and related synucleinopathies; and VXX-301, a preclinical anti-tau program under evaluation for neurodegenerative conditions such as Alzheimer’s disease, traumatic brain injury, and chronic traumatic encephalopathy. Vaxxinity is also advancing VXX-401, a phase 1 candidate intended to lower LDL cholesterol and help reduce cardiac risk, UB-313 for migraine, and UB-612, a phase 3 candidate designed to neutralize SARS-CoV-2. Incorporated in 2021, the company is headquartered in Merritt Island, Florida, and its common stock trades on OTC Markets under the symbol VAXX.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.